毕得医药(688073) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached RMB 132,381.07 million, a year-on-year increase of 20.13%[4] - Net profit attributable to shareholders of the parent company was RMB 15,220.13 million, up 29.61% compared to the previous year[4] - Basic earnings per share increased to RMB 1.75, reflecting a growth of 32.58% year-on-year[4] - The net profit excluding non-recurring gains and losses was RMB 13,312.31 million, a 27.98% increase year-on-year[4] Asset and Equity Management - Total assets at the end of 2025 amounted to RMB 251,736.28 million, representing a 4.11% increase from the beginning of the year[4] - The company achieved a weighted average return on equity of 7.54%, an increase of 1.76 percentage points year-on-year[4] Operational Efficiency - Operating profit rose by 33.14% year-on-year, driven by increased marketing investment and channel expansion[8] - The company implemented product innovation and optimized product structure to improve profitability metrics[6] Strategic Focus - The company focused on global development while enhancing domestic and overseas marketing efforts, leading to sustained growth in overseas business[6] Reporting Integrity - There are no significant uncertainties affecting the accuracy of the performance report[9]